1. Home
  2. ADPT vs PRLB Comparison

ADPT vs PRLB Comparison

Compare ADPT & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • PRLB
  • Stock Information
  • Founded
  • ADPT 2009
  • PRLB 1999
  • Country
  • ADPT United States
  • PRLB United States
  • Employees
  • ADPT N/A
  • PRLB 2415
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PRLB Metal Fabrications
  • Sector
  • ADPT Health Care
  • PRLB Industrials
  • Exchange
  • ADPT Nasdaq
  • PRLB Nasdaq
  • Market Cap
  • ADPT 1.2B
  • PRLB 1.0B
  • IPO Year
  • ADPT 2019
  • PRLB 2012
  • Fundamental
  • Price
  • ADPT $8.27
  • PRLB $40.57
  • Analyst Decision
  • ADPT Buy
  • PRLB Buy
  • Analyst Count
  • ADPT 5
  • PRLB 4
  • Target Price
  • ADPT $9.10
  • PRLB $40.33
  • AVG Volume (30 Days)
  • ADPT 1.4M
  • PRLB 273.4K
  • Earning Date
  • ADPT 02-11-2025
  • PRLB 02-07-2025
  • Dividend Yield
  • ADPT N/A
  • PRLB N/A
  • EPS Growth
  • ADPT N/A
  • PRLB 0.37
  • EPS
  • ADPT N/A
  • PRLB 0.66
  • Revenue
  • ADPT $178,957,000.00
  • PRLB $500,890,000.00
  • Revenue This Year
  • ADPT $20.07
  • PRLB $3.49
  • Revenue Next Year
  • ADPT $25.27
  • PRLB $4.82
  • P/E Ratio
  • ADPT N/A
  • PRLB $61.45
  • Revenue Growth
  • ADPT 5.10
  • PRLB N/A
  • 52 Week Low
  • ADPT $2.28
  • PRLB $25.76
  • 52 Week High
  • ADPT $8.95
  • PRLB $46.73
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 58.94
  • PRLB 44.05
  • Support Level
  • ADPT $8.09
  • PRLB $41.37
  • Resistance Level
  • ADPT $8.69
  • PRLB $45.48
  • Average True Range (ATR)
  • ADPT 0.64
  • PRLB 1.86
  • MACD
  • ADPT -0.00
  • PRLB -0.27
  • Stochastic Oscillator
  • ADPT 65.66
  • PRLB 12.38

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PRLB Proto Labs Inc. Common stock

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.

Share on Social Networks: